Rajiv I. Nijhawan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rajiv I. Nijhawan has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Divya Srivastava
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas
28 shared publications- Divya Srivastava
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas
4 shared publications Kevin Shi
4 shared publicationsAndrew Matsumoto
Department of Dermatology, University of New Mexico, Albuquerque, NM
3 shared publications- Charlotte S. Greif
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas Texas
3 shared publications - Derek Beaulieu
Tufts University School of Medicine, Boston, Massachusetts Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas
3 shared publications
Latest Publications
- 4 November 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Immune Checkpoint Inhibitors and Keratinocyte Neoplasm Risk
Was not provided for this article.
- 4 November 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Immune Checkpoint Inhibitors and Keratinocyte Neoplasm Risk
Was not provided for this article.
- 22 September 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Wide Local Excision Before Sentinel Lymph Node Biopsy May Not Affect Survival and Recurrence Outcomes in Patients With Melanoma: A TriNetX Retrospective Cohort Study
Was not provided for this article.
- 22 September 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Wide Local Excision Before Sentinel Lymph Node Biopsy May Not Affect Survival and Recurrence Outcomes in Patients With Melanoma: A TriNetX Retrospective Cohort Study
Was not provided for this article.
- 29 June 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (10) , e132-e134
Reconstruction of a Defect Involving the Upper Lip, Alar Base, and Medial Cheek
- 29 June 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (10) , e132-e134
Reconstruction of a Defect Involving the Upper Lip, Alar Base, and Medial Cheek
- 6 March 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (7) , 641
Commentary on Optimization and Prevention of Error in Surgical Site Identification
- 6 March 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (7) , 641
Commentary on Optimization and Prevention of Error in Surgical Site Identification
- 5 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (6) , 1793-1794
A retrospective cohort study of proliferating pilar tumors at a large metropolitan academic center
- 5 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (6) , 1793-1794
A retrospective cohort study of proliferating pilar tumors at a large metropolitan academic center
- 7 October 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (2) , 620-621
Skin cancer risk in bone-marrow transplant patients treated with ruxolitinib compared with other immunosuppressive therapies
- 7 October 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (2) , 620-621
Skin cancer risk in bone-marrow transplant patients treated with ruxolitinib compared with other immunosuppressive therapies
- 20 December 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 92 (4) , e123-e124
Histologic distinction and potential misidentification of proliferating pilar tumors versus squamous cell carcinoma
- 20 December 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 92 (4) , e123-e124
Histologic distinction and potential misidentification of proliferating pilar tumors versus squamous cell carcinoma
- Open Access
- 3 September 2024
- Published by Elsevier in JAAD International
- Vol. 17, 51-52
Risk of multiple primary cancers in patients with atypical fibroxanthoma/pleomorphic dermal sarcoma: A SEER analysis
- 3 September 2024
- Published by Elsevier in JAAD International
- Vol. 17, 51-52
Open AccessRisk of multiple primary cancers in patients with atypical fibroxanthoma/pleomorphic dermal sarcoma: A SEER analysis
- 9 April 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 50 (8) , 695-698
A Systematic Review of the Epidemiology, Clinical Characteristics, Treatment, and Outcomes for Desmoplastic Trichoepithelioma: Underscoring Mohs Micrographic Surgery in Management
BACKGROUND: Desmoplastic trichoepithelioma (DTE) is an uncommon benign adnexal tumor that histologically may mimic malignant tumors including basal cell carcinoma and microcystic adnexal carcinoma. OBJECTIVE: To present a systematic review of the epidemiology, clinical characteristics, treatment, and outcome data on DTEs, with emphasis on comparing Mohs micrographic surgery (MMS) with other treatments. METHODS: Using the OVID platform, MEDLINE and Embase were searched from inception for studies providing original data on DTEs. RESULTS: A total of 338 cases of DTE from 61 articles were included. No recurrence/persistence (0%) was reported following MMS (n = 24, mean follow-up of 41.9 months), 13.1% with standard excision (n = 38, mean follow-up 16.9 months), and 2.1% for electrosurgery/cautery (n = 49, follow-up 3–72 months). 100% recurrence/persistence for imiquimod (n = 2) and liquid nitrogen (n = 4) were identified. In patients who underwent biopsy only, there was a 12.5% recurrence/persistence (n = 32, mean follow-up 16.5 months). Overall, duration of follow-up varied from 2 months to 6 years for the various management strategies. CONCLUSION: Data are limited regarding DTE outcomes. In this review, surgical modalities, specifically MMS, had the lowest rates of recurrence/persistence compared with other options. Given that most lesions are found on cosmetically sensitive locations, MMS seems to be the optimal management strategy for actively managing DTEs.
- 9 April 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 50 (8) , 695-698
A Systematic Review of the Epidemiology, Clinical Characteristics, Treatment, and Outcomes for Desmoplastic Trichoepithelioma: Underscoring Mohs Micrographic Surgery in Management
BACKGROUND: Desmoplastic trichoepithelioma (DTE) is an uncommon benign adnexal tumor that histologically may mimic malignant tumors including basal cell carcinoma and microcystic adnexal carcinoma. OBJECTIVE: To present a systematic review of the epidemiology, clinical characteristics, treatment, and outcome data on DTEs, with emphasis on comparing Mohs micrographic surgery (MMS) with other treatments. METHODS: Using the OVID platform, MEDLINE and Embase were searched from inception for studies providing original data on DTEs. RESULTS: A total of 338 cases of DTE from 61 articles were included. No recurrence/persistence (0%) was reported following MMS (n = 24, mean follow-up of 41.9 months), 13.1% with standard excision (n = 38, mean follow-up 16.9 months), and 2.1% for electrosurgery/cautery (n = 49, follow-up 3–72 months). 100% recurrence/persistence for imiquimod (n = 2) and liquid nitrogen (n = 4) were identified. In patients who underwent biopsy only, there was a 12.5% recurrence/persistence (n = 32, mean follow-up 16.5 months). Overall, duration of follow-up varied from 2 months to 6 years for the various management strategies. CONCLUSION: Data are limited regarding DTE outcomes. In this review, surgical modalities, specifically MMS, had the lowest rates of recurrence/persistence compared with other options. Given that most lesions are found on cosmetically sensitive locations, MMS seems to be the optimal management strategy for actively managing DTEs.